Side-by-side · Research reference

EpitalonvsGLP-1 (7-37)

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED8/37 cited

BHuman-MechanisticHUMAN-REVIEWED16/43 cited

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

GLP-1 (7-37)

Incretin Hormone · Native Peptide

~2 minHalf-lifeAlavi 2021 Ding 2017

3297.7 DaMolecular weightAlavi 2021

1922Discovery year

Research use only · IV/SC in experimental settings

01Mechanism of Action

Parameter

Epitalon

GLP-1 (7-37)

Primary target

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

GLP-1 receptor (class B GPCR)Koole 2015

Pathway

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

GLP-1R activation → cAMP production → PKA signaling → insulin secretion (pancreatic β-cells)Lu 2025 Koole 2015

Downstream effect

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

Glucose-dependent insulin release, glucagon suppression, delayed gastric emptying, reduced food intakeLu 2025 Ding 2017

Feedback intact?

—

Yes — physiological secretion and degradation preserved

Origin

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

Endogenous peptide cleaved from proglucagon in intestinal L cells; secreted postprandially

Antibody development

—

02Dosage Protocols

Parameter

Epitalon

GLP-1 (7-37)

Standard dose

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

—

Frequency

Once daily during a cycle

—

Lower / starter dose

2.5 mg / day

—

Evidence basis

In-vitro telomerase + Russian clinical trialsKhavinson 2003

—

Duration

10–20 day cycles, 1–2× per year

—

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep preferred (pineal alignment)

—

Half-life

Hours (estimated)

~2 minutes (plasma)Alavi 2021 Ding 2017

Requires continuous infusion for sustained effect.

Clinical use

—

None — native GLP-1 not used therapeutically

Engineered analogues (semaglutide, liraglutide) used clinically.Friedman 2024

Research dosing

—

Variable — 0.1–10 nmol/kg in animal models

Used as reference standard for analogue comparison.

Modified analogues

—

t½ extended to 13 h (liraglutide), 165 h (semaglutide)

Via DPP-4 resistance + fatty acid acylation.

03Metabolic / Fat Loss Evidence

Parameter

Epitalon

GLP-1 (7-37)

Mechanism

—

GLP-1R activation in hypothalamic satiety centers (arcuate nucleus) reduces food intakeLu 2025

Effect demonstrated with long-acting analogues (liraglutide).Lu 2025

Native GLP-1 efficacy

—

Minimal — rapid degradation prevents sustained appetite suppression

Gastric emptying

—

Delayed in animal models, contributing to satiety

Body weight impact

—

Not observed with native GLP-1 — requires analogue formulations

04Side Effects & Safety

Parameter

Epitalon

GLP-1 (7-37)

Injection site reaction

Mild irritation

—

Sleep architecture

Improved subjective sleep quality (anecdotal)

—

Cancer risk

Theoretical via telomerase activation in pre-malignant cells

—

Long-term safety

Limited Western RCT data

—

Pregnancy / OB

Avoid

—

Antibody formation

Not reported

—

Native GLP-1

—

Well-tolerated in research settings; no prolonged exposure data

Hypoglycemia risk

—

Low — insulin secretion is glucose-dependent

Analogue side effects

—

Nausea, vomiting, diarrhea (GLP-1R agonists)

Not applicable to native GLP-1 due to non-therapeutic use.

GLP-1 resistance

—

High glucose-induced PKCβ overexpression may reduce GLP-1 responsiveness in endothelial cellsPujadas 2016

Absolute Contraindications

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

GLP-1 (7-37)

—

Relative Contraindications

Epitalon

·Family history of cancer

GLP-1 (7-37)

—

05Administration Protocol

Parameter

Epitalon

GLP-1 (7-37)

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

Native GLP-1(7-37) is not formulated for therapeutic use. Administered IV or SC in experimental protocols to study GLP-1R pharmacology and as reference standard for analogue development.

2. Injection site

SQ — abdomen preferred. Rotate sites.

Lyophilised peptide stored at -20°C or below. Reconstituted solutions should be prepared fresh and used immediately due to rapid degradation.

3. Timing

Pre-sleep preferred to align with pineal axis.

For therapeutic GLP-1R activation, use FDA-approved long-acting analogues: semaglutide (once weekly), liraglutide (once daily), dulaglutide (once weekly), or exenatide (twice daily or once weekly).

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

—

5. Needle

29–31G, 4–8 mm insulin syringe.

—